Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1733130 | 0.80 | NR4A2 (0.73) | NR4A2CYP2C9TGFBR1MCHR1EGLN1 | |
| SCHEMBL3767161 | 0.79 | NR4A2 (0.61) | NR4A2CYP2C9 | |
| SCHEMBL1728471 | 0.78 | NR4A2 (0.70) | NR4A2CYP2C9TGFBR1MCHR1EGLN1 | |
| SCHEMBL3769993 | 0.78 | APP (0.44) | EGLN1 | |
| Hydrochloric Acid SCHEMBL3766428 | 0.77 | NR4A2 (0.69) | NR4A2CYP2C9TGFBR1MCHR1EGLN1 | |
| Hydrochloric Acid SCHEMBL3777031 | 0.77 | NR4A2 (0.69) | NR4A2CYP2C9TGFBR1MCHR1EGLN1 | |
| SCHEMBL2086662 | 0.75 | HRH4 (0.52) | EGLN1 | |
| SCHEMBL1500384 | 0.75 | APP (0.47) | EGLN1 | |
| SCHEMBL8817882 | 0.75 | ABL1 (0.48) | MCHR1 | |
| SCHEMBL1732978 | 0.74 | NR4A2 (0.80) | NR4A2CYP2C9MCHR1EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317688-A1 | 2-HETEROAROYLIMIDAZOL[1,2-a]PYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-12-16 | — | — | US | claimed |
| US-20100317688-A1 | 2-HETEROAROYLIMIDAZOL[1,2-a]PYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-12-16 | — | — | US | disclosed |
| EP-2240480-A2 | DERIVATIVES OF 2-HETEROAROYL-IMIDAZOL(1,2-A)PYRIDINE,PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | Sanofi-Aventis (FR) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009106752-A2 | DERIVATIVES OF 2-HETEROAROYL-IMIDAZOL[1,2-A]PYRIDINE, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317688-A1 | 2-HETEROAROYLIMIDAZOL[1,2-a]PYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | XDH, CYP11B2, IL4I1 | NR4A2 3136/4885CYP2C9 305/4885TGFBR1 3854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.